Article

Interview: Inclusion of Health-Related Quality of Life (HRQoL) and other Patient-Reported Outcomes (PROs) in the United States Food and Drug Administration (FDA) labels

Sarah Cadarette, MPH

Discover insights from ISPOR US 2025

A conversation with Sarah Cadarette

In anticipation of the 2025 ISPOR meeting, we had the opportunity to speak with Sarah Cadarette, Associate Director, Evidence Generation & Value Communications, to discuss her poster Inclusion of Health-Related Quality of Life (HRQoL) and Other Patient-Reported Outcomes (PROs) in the United States Food and Drug Administration (FDA) Labels on patient-reported outcomes (PROs) and their presence on FDA labels. Sarah shared her insights and findings, shedding light on the importance of PROs in clinical trials and drug labeling. Malia Gill, Brittany Galloway, Nicole Fusco, Maria Koufopoulou, and Erika Wissinger served as co-authors.

Download the poster

What inspired this research?

Sarah Cadarette: The inspiration for this research stemmed from the growing interest in patient-reported outcomes (PROs) over the last decade, particularly within the United States, where historically they have not been a major focus for regulatory decisions. My team frequently encounters questions about PROs and quality of life during literature reviews. This led us to investigate whether these outcomes are being evaluated in registrational trials and if they translate to FDA labels, which are crucial for healthcare providers and patients. The research aimed to understand the role of PROs in various therapeutic areas and how they are perceived in regulatory contexts.

Was there a hypothesis that was confirmed through the research?

Sarah Cadarette: While there was no formal hypothesis, we correctly anticipated that there wouldn't be much representation of PROs on FDA labels. This assumption was confirmed through our research, particularly in the therapeutic areas chosen for the study. The team considered a range of conditions, including rheumatoid arthritis, asthma, and of non-small cell lung cancer (NSCLC), to cover the spectrum of where PROs are clinically important. The expectation was that rheumatoid arthritis would show the most PROs, while NSCLC would show the least. This aligned with their findings.

What are the key takeaways from your research?

Sarah Cadarette: Our research revealed that there is a significant variety in the tools used for PROs across different trials, especially in the context of non-small cell lung cancer (NSCLC). However, there were not many labels that included PROs, which was somewhat expected. The study highlighted the importance of considering PROs during the early planning stages of clinical trials, as they are becoming more important for different stakeholders for measuring outcomes like efficacy in conditions such as rheumatoid arthritis. The findings underscore the need for consistency in using PROs across drugs to facilitate better comparisons.

Was there anything in the research that was surprising, that you didn't expect, that you found out?

Sarah Cadarette: One surprising element in the research was the variety of tools used for PROs in NSCLC trials. Although there were not many labels including PROs, the diversity in the tools employed was greater than anticipated. This unexpected finding suggests that while PROs may not be prominently featured on labels, they are being considered in trial designs to a certain extent. This variety indicates a broader interest in exploring different methods for capturing patient experiences, even if they are not yet reflected in labeling practices.

What are the next steps from this research?

Sarah Cadarette: This research is a valuable tool for planning clinical trials and developing evidence generation plans. By understanding what PROs have been previously used and their presence on labels, biopharma can better design their trials to include relevant outcomes. This research also serves as a landscape assessment, offering insights into the types of PROs that could be beneficial to include in future trials. The next steps involve using these findings to aid in the strategic planning of trial programs, ensuring that PROs are effectively integrated into drug development processes.

Citations relevant to the content described herein are provided in the poster mentioned here. Readers should review all available information related to the topics mentioned herein and rely on their own experience and expertise in making decisions related thereto.

Connect with our team

Our team of leading value experts is dedicated to transforming evidence, policy insights, and market intelligence into effective global market access strategies. Let us help you navigate today’s complex healthcare landscape with confidence. Reach out to discover how we can support your goals.

Related resources

Article

RAPS Convergence 2025: Transparency, Trust, and Resilience in Regulatory Science

Learn more

Article

The complex path to meeting promotional materials requirements in Europe

Learn more

Article

The critical role of industry in the PMS and master data

Learn more

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.